HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
Seaport Therapeutics
Seaport Therapeutics SPTX | 0.00 |
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:
SPTX) with a Buy rating and announces Price Target of $50.
